AI in Clinical Trials Market Size, Trends and Research in 2026 in UK, Europe, US and Canada

The global AI in clinical trials market is projected to reach $2.8-3.5 billion by 2026, with North America commanding 35% market share and the UK showing the fastest growth rate in Europe as pharmaceutical companies accelerate digital transformation.

Published: December 12, 2025 By Marcus Rodriguez Category: Health Tech
AI in Clinical Trials Market Size, Trends and Research in 2026 in UK, Europe, US and Canada

Executive Summary

The artificial intelligence revolution in clinical trials is accelerating at unprecedented pace, with the global market projected to reach $2.8-3.5 billion by 2026 according to Grand View Research. North America maintains market leadership with approximately 35% global share, while the United Kingdom demonstrates the fastest growth trajectory in Europe.

Industry analysts project the market will expand to $6-8 billion by 2030, with more aggressive forecasts from Precedence Research suggesting potential growth to $22.36 billion by 2034 at a 27.05% compound annual growth rate.

Global AI Clinical Trials Market Projections 2024-2030

Year Conservative Mid-Range Aggressive
2024 $1.35B $1.9B $2.04B
2025 $2.14B $2.5B $2.7B
2026 $2.5B $3.0B $3.5B
2030 $2.74B $7.8B $22.36B

[AI-GENERATED INFOGRAPHIC: Global AI Clinical Trials Market Growth Trajectory 2024-2030 - Visual showing market expansion across regions with key milestones and growth drivers]

Regional Market Analysis 2026

Region 2026 Market Size Global Share Key Growth Driver
North America (US + Canada) $1.0B - $1.5B 33-35% FDA 21st Century Cures Act
Europe (including UK) $0.7B - $1.0B 25-28% EMA AI guidance framework
Asia-Pacific $0.8B - $1.2B 28-32% Emerging pharma sector
Rest of World $0.3B - $0.5B 10-12% Healthcare digitization

United States: Market Leadership

The United States commands approximately 60-65% of the North American market, driven by the world's highest concentration of clinical trials representing 23% of global trial activity. According to MarketsandMarkets, the FDA's 21st Century Cures Act has accelerated AI adoption by promoting real-world evidence integration.

Major pharmaceutical companies including Pfizer...

Read the full article at AI BUSINESS 2.0 NEWS